Another contributing factor will be how many BPs are interested. If it's only 1, then they are in a position of strength. If there are others then the pendulum moved back to Pharmaust. Also if they are chasing a licensing deal the they will only look at the potential revenue from that application. In a buyout the whole of the potential will come into consideration.
As NZ said, there is a lot to consider. And probably things we are not even aware of.
PAA Price at posting:
9.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)